Serum vascular endothelial growth factor and COX-2/5-LOX inhibition in advanced non-small cell lung cancer: Cancer and leukemia group B 150304

Journal of Thoracic Oncology

Volumn 6, Issue 11, 2011, Pages 1902-1906

  Edelman, Martin J ^a   Hodgson, Lydia ^b   Wang, Xiaofei ^b   Christenson, Robert ^a   Jewell, Scott ^c   Vokes, Everett ^d   Kratzke, Robert ^e  

^a UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER   (United States)

^b DUKE UNIVERSITY   (United States)

^c OHIO STATE UNIVERSITY   (United States)

^d UNIVERSITY OF CHICAGO   (United States)

^e UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Celecoxib; Eicosanoid; Lung cancer; VEGF

Indexed keywords

ARACHIDONATE 5 LIPOXYGENASE; CARBOPLATIN; CELECOXIB; CYCLOOXYGENASE 2; GEMCITABINE; VASCULOTROPIN; ZILEUTON;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; DRUG RESPONSE; ENZYME INHIBITION; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SURVIVAL TIME; TREATMENT OUTCOME;

EID: 80054910709     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e31822a7383     Document Type: Article

References (20)

1. Hicklin DJ, Ellis LM. Role of vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005;23:1011-1027. (Pubitemid 46202320)
2. Gallo O, Franchi A, Magnelli L, et al. Cyclooxygenase-2 pathway correlated with VEGF expression in head and neck cancer. Implications for tumor angiogenesis and metastasis. Neoplasia 2001;3:53-61. (Pubitemid 32201610)
3. Cianchi F, Cortesini C, Bechi P, et al. Up-regulation of cyclooxygenase 2 gene expression correlates with tumor angiogenesis in human colorectal cancer. Gastroenterology 2001;121:1339-1347. (Pubitemid 33140451)
4. Marrogi AJ, Travis WD, Welsh JA, et al. Nitric oxide synthase, cyclo-oxygenase2 and vascular endothelial growth factor in the angiogenesis of non-small cell lung cancer. Clinical Cancer Res 2000;6:4739-4744. (Pubitemid 32110413)
5. Soo RA, Wu J, Aggarawal A, et al. Celecoxib reduces microvessel density in patients treated with nasopharyngeal carcinoma and induces changes in gene expression. Ann Onc 2006;17:1625-1630. (Pubitemid 44680881)
6. Romano M, Catalano A, Nutini M, et al. 5-lipoxygenase regulates malignant mesothelial cell survival: involvement of vascular endothelial growth factor. FASEB J 2001;15:2326-2336. (Pubitemid 33063161)
7. Ye YN, Liu ES, Shin VY, et al. Contributory role of 5-lipoxygenase and its association with angiogenesis in the promotion of inflammation-associated colonic tumorigenesis by cigarette smoking. Toxicology 2004;203:179-188. (Pubitemid 39200948)
8. Edelman MJ, Watson D, Xiaofei W, et al. Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy-Cancer and Leukemia Group B Trial 30203. J Clin Oncol 2008;26:848-855. (Pubitemid 351398075)
9. Rosenblatt PY. Edelman MJ, Christenson RH, et al. CYFRA 21-1 (CYFRA) as a prognostic and predictive marker in advanced non-small cell lung cancer (NSCLC): CALGB 150304. J Clin Oncol 2009; 27(suppl):562s(abstract).
10. McShane LM, Altman DG, Sauerbrei W, et al. Reporting recommendations for tumor marker prognostic studies. J Clin Oncol 2005;23:9067-9072.
11. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355: 2542-2550. (Pubitemid 44917502)
12. Erratum in: N Engl J Med 2007;356:318.
13. Reck M, von Pawel J, Zatloukal P, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol. 2009; 27:1227-1234.
14. Erratum in: J Clin Oncol 2009;27:2415.
15. Horn L, Sandler A. Epidermal growth factor receptor inhibitors and antiangiogenic agents for the treatment of non-small cell lung cancer. Clin Cancer Res 2009;15:5040-5048.
16. Gately S, Li WW. Multiple roles of COX-2 in tumor angiogenesis: a target for antiangiogenic therapy. Semin Oncol 2004;31(2 suppl 7):2-11. (Pubitemid 38879409)
17. Kido Y. Vascular endothelial growth factor (VEGF) serum concentration changes during chemotherapy in patients with lung cancer. Kurume Med J2001;48:43-47. (Pubitemid 32578294)
18. Chien MH, Ku CC, Johansson G, et al. Vascular endothelial growth factor-c (VEGF-C) promotes angiogenesis by induction of COX-2 in leukemic cells via the VEGF-R3/JNK/AP-1 pathway. Carcinogenesis 2009;30:2005-2013.
19. Brattstrom D, Bergvist M, Hesselius P, et al. Elevated preoperative serum levels of angiogenic cytokines correlate to larger primary tumors and poorer survival in non-small cell lung cancer patients. Lung Cancer 2002;37:57-63. (Pubitemid 34621459)
20. Dowlati A, Gray R, Sandler AB, et al. Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizumab-an Eastern Cooperative Oncology Group Study. Clin Cancer Res 2008;14:1407-1412. (Pubitemid 351413922)